NCT03185364

The Safety and Efficiency of Sildenafil in the Treatment of Severe Post-capillary Pulmonary Hypertension Caused by COPD

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital · Academic / Other
• Sex: All
• Age: 40 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Over half of chronic obstructive pulmonary disease (COPD) patients develop pulmonary hypertension. The current therapy focuses only on the basic disease and there are a lot of controversies about the use of PAH target therapy in group 3 pulmonary hypertension. Our study is to explore whether sildenafil, a pulmonary arterial hypertension (PAH) target drug, could be efficient and safe in improving symptoms and survival of severe pulmonary hypertension caused by COPD.

Conditions

• COPD
• Pulmonary Hypertension

Interventions

Type	Name	Description
DRUG	Sildenafil Citrate	sildenafil treatment for 12 weeks, monitoring blood pressure and other adverse events
DRUG	Placebo Oral Tablet	placebos treatment for 12 weeks

Timeline

• Start date: 2017-06-15
• Primary completion: 2020-12-31
• Completion: 2020-12-31
• First posted: 2017-06-14
• Last updated: 2017-06-14

Locations

1 site across 1 country: China